Skip to main content
. 2021 Apr 23;2021:6635084. doi: 10.1155/2021/6635084

Figure 3.

Figure 3

Changes in NMDAR and CaMKII subunits after ketamine administration. (a) Representative immunoblots and NMDAR2-α (NR2A or NMDAR2A) expressions in the hippocampal DG of various study subjects. (b) Representative immunoblots and NMDAR2-β (NR2B or NMDAR2B) expressions in the hippocampal DG of various groups after ketamine. (c) Relative mRNA expression of CaMK2A in the hippocampal DG region of the brain. (d) Representative immunoblots and protein expression of CaMK2A in the DG region of various test subjects. (e) Relative mRNA expression of CaMK2B in the hippocampal DG region of various study groups. (f) Representative immunoblots and protein expression of CaMK2B in the hippocampal DG region of the brain. (g) Protein levels of the phosphorylated state of CaMK2A (pCaMK2A or phospCaMK2A) in different groups. (h) Representative immunoblots of pCaMK2A expressions. (i) Representative immunoblots and protein levels of the phosphorylated state of CaMK2B (pCaMK2B or phospCaMK2B) in the GD region of various experimental subjects. 1w = 1 week. MCAO+c: MCAO+CUMS; MCAO+c+k: MCAO+CUMS+ketamine. One-way ANOVA followed by Tukey's multiple comparison tests. n = 6 per group. ∗p < 0 05, ∗∗p < 0.005, ∗∗∗p < 0.0005, and ∗∗∗∗p < 0.0001.